The enclosed Management Discussion and Analysis (MD&A) provides an overview of the company''s consolidated and standalone financial and key operational highlights, and the future outlook ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Qualitek Labs achieved a major milestone in FY26, crossing ₹125 Crore in consolidated revenue—a 77% jump from FY25 and a fourfold increase over FY24. H2 FY26 revenue stood at ₹70.27 Crore with PAT of ₹9.89 Crore, driven by strong operating leverage and successful integration of Interstellar Testing Centre. The company expanded its lab network to 10 owned and 6 PPP labs across India, adding a USFDA-approved pharmaceutical lab in Bengaluru and a food testing lab in Mumbai. Consolidated EBITDA margin improved to 25.7% in H2 FY26 from 19.7% a year earlier, while gross margins expanded to 87%. Total assets grew to ₹270.84 Crore and net worth to ₹152.49 Crore, supported by retained earnings and equity infusion.
The strong FY26 results demonstrate consistent execution on the company's growth strategy with improving margins. Management's FY27 guidance of 35-40% revenue growth and 15-17% PAT margin appears achievable given the H2 FY26 exit run-rate. The medium-term target of ₹500 Crore revenue by FY31 positions Qualitek as a growing mid-cap in the testing, inspection and certification (TIC) sector.